治疗肺动脉高压新药-Selexipag研究进展
发布时间：2018-10-14 19:42
【摘要】：肺动脉高压是以血管收缩、血管重构、平滑肌细胞增殖和原位血栓形成等为主要特征的肺小动脉异常疾病。Selexipag是一种新型口服前列环素受体激动剂,已被证明可改善Ⅱ期临床试验的血液动力学,并可减少Ⅲ期临床试验中肺动脉高压患者的疾病恶化情况。本文对其作用机制、药动学、药效学、临床试验、不良反应等方面做一综述。
[Abstract]:Pulmonary hypertension is a pulmonary arteriolar abnormality characterized by vasoconstriction, vascular remodeling, smooth muscle cell proliferation and in situ thrombosis. Selexipag is a novel oral prostacyclin receptor agonist. It has been shown to improve hemodynamics in phase II clinical trials and to reduce the deterioration of pulmonary hypertension in phase 鈪，
本文编号：2271453
[Abstract]:Pulmonary hypertension is a pulmonary arteriolar abnormality characterized by vasoconstriction, vascular remodeling, smooth muscle cell proliferation and in situ thrombosis. Selexipag is a novel oral prostacyclin receptor agonist. It has been shown to improve hemodynamics in phase II clinical trials and to reduce the deterioration of pulmonary hypertension in phase 鈪，
本文编号：2271453
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2271453.html
最近更新
教材专著
